drugset / Trial / NCT01698697

Comparison of Two Insulin Aspart Formulations in Healthy Volunteers

NCT01698697

Phase 1 Completed 24 enrolled Novo Nordisk A/S
RandomizedCrossoverDouble-blindTreatment

Summary

This trial is conducted in Africa. The aim of this trial is to determine if a new formulation (U200) of insulin aspart containing 200 U/mL is bioequivalent to that of a marketed insulin aspart formulation (U100).

Timeline

Start
2002-09-02
Primary completion
2002-10-18
Completion
2002-10-18

Drugs

EvaluationDrugModalityDoseRoute
Subject insulin aspart Protein / enzyme biologic 0.029 iu/kg Subcutaneous

Indications